Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors.Sakurada, I., Endo, T., Hikita, K., Hirabayashi, T., Hosaka, Y., Kato, Y., Maeda, Y., Matsumoto, S., Mizuno, T., Nagasue, H., Nishimura, T., Shimada, S., Shinozaki, M., Taguchi, K., Takeuchi, K., Yokoyama, T., Hruza, A., Reichert, P., Zhang, T., Wood, H.B., Nakao, K., Furusako, S.
(2017) Bioorg Med Chem Lett 27: 2622-2628
- PubMed: 28408226
- DOI: https://doi.org/10.1016/j.bmcl.2017.03.002
- Primary Citation of Related Structures:
- PubMed Abstract:
Using structure based drug design, novel aminobenzisoxazoles as coagulation factor IXa inhibitors were designed and synthesized. Highly selective inhibition of FIXa over FXa was demonstrated. Anticoagulation profile of selected compounds was evaluated by aPTT and PT tests. In vitro ADMET and pharmacokinetic (PK) profiles were also evaluated.
Discovery Research, Mochida Pharmaceutical Co. Ltd., 722 Uenohara, Jimba, Gotemba, Shizuoka 412-8524, Japan. Electronic address: email@example.com.